Skip to main content
S&P 5007,688.62+1.58%DOW53,356.12+3.03%NASDAQ25,736.51+1.44%BTC$80,787.00+5.07%ETH$2,431.65+7.47%GOLD$4,134.30+1.51%OIL$87.17-1.08%
Smart Investors Daily
SID Premium
RN

NASDAQ · RNXT

RenovoRx, Inc.

Healthcare · Biotechnology

$1.31

Up+$0.02 (+1.55%)

Updated Nov 5, 2026, 4:21 AM

SID Score

5.6/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
36.39M
P/E ratio
-3.41
Dividend yield
0.00%
52-week range
$0.77 – $2.59
Volume
217.51K
Avg. volume
506.07K

Price performance · RNXT

RNXT price history

1M range · 0 trading sessions · Daily adjusted prices

RNXT does not have enough price history for the selected period.

Data unavailable

Market data is busy. Please try again shortly.

Latest RNXT news

The latest Smart Investors Daily articles mentioning RNXT.

Stock researchCompany · Overview

RNXT research

Overview

Company profile and research snapshot.

Company profile

RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
RNXT recent ratings
DateFirmRatingTarget
Aug 28, 2026Ascendiant CapitalBuy—
Jun 1, 2026Ascendiant CapitalBuy—
Apr 9, 2026Ascendiant CapitalBuy—
Apr 8, 2026HC Wainwright & Co.Buy—
Feb 17, 2026Ascendiant CapitalBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 28, 2026

RenovoRx to Participate at the Canaccord Genuity MedTech Diagnostics and Digital Health & Services Forum

MOUNTAIN VIEW, Calif., Oct. 28, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or “the Company”) (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a patented, FDA-cleared drug-delivery device, today announced that Shaun Bagai, Chief Executive Officer, and Mark Voll, Chief Financial Officer, are scheduled to present at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum being held on November

Yahoo · Oct 22, 2026

RenovoRx to Report Third Quarter 2026 Financial Results and Business Highlights on November 5, 2026

Company to host conference call on November 5, 2026, at 4:30 p.m. ETMOUNTAIN VIEW, Calif., Oct. 22, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a patented, FDA-cleared drug-delivery device, today announced that it will release third quarter 2026 financial results and business highlights after market close on Thursday, November 5, 2026. RenovoRx will

Yahoo · Oct 7, 2026

RenovoRx Advances TAMP™ into Borderline Resectable Pancreatic Cancer with First Patient Enrolled in Investigator-Initiated PRISM-TAMP Trial

University of Vermont-Sponsored IIT Explores TAMP in a New Clinical Setting: TAMP Utilization Prior to Surgical ResectionMOUNTAIN VIEW, Calif., Oct. 07, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or “the Company”) (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a patented, FDA-cleared drug-delivery device, announced today that the first patient has enrolled in PRISM-TAMP, “PDAC Regression and Intraoperative Surgi

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By